Literature DB >> 20582912

Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis.

Jeffrey C Munson1, Maryl Kreider, Zhen Chen, Jason D Christie, Stephen E Kimmel.   

Abstract

PURPOSE: Idiopathic pulmonary fibrosis (IPF) has not been shown to respond to corticosteroid therapy; however, many patients receive these drugs at the time of diagnosis. The factors that are associated with the decision to prescribe corticosteroids have not been examined.
METHODS: We conducted a retrospective cohort study of 1126 patients with a new diagnosis of IPF using The Health Improvement Network (THIN) database from the United Kingdom. We used generalized estimating equation (GEE) regression models to test the association of patient characteristics, co-morbid diseases, and disease characteristics with the use of corticosteroids within 30 days of IPF diagnosis.
RESULTS: Bivariable analyses demonstrated an association between female sex, the presence of dyspnea, the need for oxygen, past steroid use, and the use of corticosteroids immediately prior to diagnosis with the use of corticosteroids at the time of diagnosis. After adjustment with multivariable GEE regression, only the use of oxygen at the time of diagnosis (OR 1.69, CI 1.14-2.49), the past use of corticosteroids (OR 1.50, CI 1.04-2.15), and use of corticosteroids immediately prior to diagnosis (OR 5.72, CI 3.80-8.60) remained significantly associated with the use of corticosteroids immediately following diagnosis. No association was found between prior diabetes, osteoporosis, glaucoma, hypertension, congestive heart failure, obesity, or peptic ulcer disease and use of corticosteroids at diagnosis.
CONCLUSIONS: The decision to prescribe corticosteroids is associated with oxygen use and past corticosteroid use but is not influenced by factors such as age, gender, or common co-morbid conditions that may pre-dispose patients to adverse events of therapy. (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582912      PMCID: PMC2898153          DOI: 10.1002/pds.1959

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  20 in total

1.  British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.

Authors:  I D Johnston; R J Prescott; J C Chalmers; R M Rudd
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

3.  Idiopathic pulmonary fibrosis: predicting response to therapy and survival.

Authors:  S E Gay; E A Kazerooni; G B Toews; J P Lynch; B H Gross; P N Cascade; D L Spizarny; A Flint; M A Schork; R I Whyte; J Popovich; R Hyzy; F J Martinez
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

4.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

5.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

6.  The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis.

Authors:  R Hubbard; A Venn
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

7.  The relationship between time since registration and measured incidence rates in the General Practice Research Database.

Authors:  James D Lewis; Warren B Bilker; Rachel B Weinstein; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-07       Impact factor: 2.890

8.  Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study.

Authors:  K J Mortimer; L J Tata; C J P Smith; J West; T W Harrison; A E Tattersfield; R B Hubbard
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

9.  Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death.

Authors:  R Hubbard; S Lewis; C Smith; C Godfrey; L Smeeth; P Farrington; J Britton
Journal:  Tob Control       Date:  2005-12       Impact factor: 7.552

10.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.

Authors:  Liam Smeeth; Claire Cook; Sara Thomas; Andrew J Hall; Richard Hubbard; Patrick Vallance
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

View more
  2 in total

1.  Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.

Authors:  Alison C Mackinnon; Michael A Gibbons; Sarah L Farnworth; Hakon Leffler; Ulf J Nilsson; Tamara Delaine; A John Simpson; Stuart J Forbes; Nik Hirani; Jack Gauldie; Tariq Sethi
Journal:  Am J Respir Crit Care Med       Date:  2011-11-17       Impact factor: 30.528

2.  AITC inhibits fibroblast-myofibroblast transition via TRPA1-independent MAPK and NRF2/HO-1 pathways and reverses corticosteroids insensitivity in human lung fibroblasts.

Authors:  Jennifer Maries Go Yap; Takashi Ueda; Yoshihiro Kanemitsu; Norihisa Takeda; Kensuke Fukumitsu; Satoshi Fukuda; Takehiro Uemura; Tomoko Tajiri; Hirotsugu Ohkubo; Ken Maeno; Yutaka Ito; Testsuya Oguri; Shinya Ugawa; Akio Niimi
Journal:  Respir Res       Date:  2021-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.